Buscar
GH Research PLC
GHRSAñadir a la lista de seguimiento
28.070USD
-0.310-1.09%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
1.92BCap. mercado
PérdidaP/E TTM
Más Datos de GH Research PLC Compañía
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Información de GH Research PLC
Símbolo de cotizaciónGHRS
Nombre de la empresaGH Research PLC
Fecha de salida a bolsaJun 25, 2021
Director ejecutivoValcheva (Velichka)
Número de empleados50
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 25
DirecciónJoshua Dawson House
CiudadDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postalD02 RY95
Teléfono35314378334
Sitio Web
Símbolo de cotizaciónGHRS
Fecha de salida a bolsaJun 25, 2021
Director ejecutivoValcheva (Velichka)
Ejecutivos de GH Research PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Velichka (Villy) Valcheva, M.D.
Dr. Velichka (Villy) Valcheva, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de GH Research PLC?
Los cinco principales accionistas de GH Research PLC son: Mr. Florian Schonharting
¿Cuántas instituciones poseen acciones de GH Research PLC (GHRS)?
A fecha de 2026Q1, 109 instituciones poseen acciones de GH Research PLC, con un valor de mercado combinado de aproximadamente 46.87M, lo que representa el 68.37% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -3238705.00.